Collegium Pharma (COLL) Stock Price, Quote & News

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 713 3699

Website: www.collegiumpharma.com

Address:

100 Technology Center Drive, Suite 300, Stoughton, United States

Iightning Dec. 4 at 10:49 PM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $45C Entry: 3.33 Exit: 6.29 Return: +89.18% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 6:30 AM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $50C Entry: 0.88 Exit: 1.26 Return: +44.35% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 10:07 AM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $25C Entry: 22.65 Exit: 38.25 Return: +68.89% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 12:47 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $COLL **Contract:** Dec 19 $50C **Entry:** 1.27 **Exit:** 2.41 **Return:** **+89.35% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 3:40 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:46 PM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:39 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Estimize Nov. 24 at 1:03 PM

Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

KirRoyalTrader Nov. 23 at 10:02 PM

$UVE $INVA $COLL $APPN

0 · Reply

evanmedeiros Nov. 23 at 5:10 PM

Nice high tight flag setting up here in Collegium Pharmaceutical. Watchlists still loaded with pharma stocks as technology continues its sell off. Chart found from @InvestorsBusinessDaily MarketSurge https://research.investors.com/stock-quotes/nasdaq-COLL-inc-COLL.htm?utm_source=Evan_Medeiros&utm_medium=stocktwits&utm_campaign=SOCIAL+INFLUENCER&utm_id=SCINFLUENCER&utm_content=leaderboard#performance%3Fsrc=A00616 $COLL #IBDPartner

0 · Reply

Collegium to Participate in Upcoming Investor Conferences

Nov 10, 2025, 4:27 PM EST - 24 days ago

Collegium Pharmaceutical: Another Solid Quarter

Nov 6, 2025, 10:06 PM EST - 27 days ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Oct 30, 2025, 5:15 PM EDT - 5 weeks ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 8:00 AM EDT - 6 weeks ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 13, 2025, 8:00 AM EDT - 7 weeks ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Sep 8, 2025, 5:03 PM EDT - 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 3 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 7, 2025, 2:00 PM EDT - 4 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:51 AM EDT - 4 months ago

Collegium (COLL) Q2 Revenue Jumps 29%

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 8:00 AM EDT - 5 months ago

Collegium Announces $150 Million Share Repurchase Program

Jun 30, 2025, 2:53 PM EDT - 5 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

May 12, 2025, 8:05 AM EDT - 7 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 9, 2025, 2:04 AM EDT - 7 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 7 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 9 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 9 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 10, 2025, 6:57 PM EDT - 9 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 9, 2025, 4:07 AM EDT - 9 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Feb 27, 2025, 9:03 PM EST - 9 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 10 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 8:00 AM EST - 10 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Jan 8, 2025, 8:00 AM EST - 11 months ago

Collegium Provides 2025 Financial Guidance and Business Update

Nov 26, 2024, 8:00 AM EST - 1 year ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Feb 22, 2024, 9:52 PM EST - 1 year ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:09 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 8, 2024, 8:00 AM EST - 1 year ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Nov 27, 2023, 8:00 AM EST - 2 years ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 7, 2023, 10:15 PM EST - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 2 years ago

Collegium Reports Third Quarter 2023 Financial Results

Iightning Dec. 4 at 10:49 PM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $45C Entry: 3.33 Exit: 6.29 Return: +89.18% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 6:30 AM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $50C Entry: 0.88 Exit: 1.26 Return: +44.35% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 10:07 AM

1ightning® Premium Options Alert (Actionable) Ticker: $COLL Contract: Dec 19 $25C Entry: 22.65 Exit: 38.25 Return: +68.89% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 12:47 AM

0 · Reply

Iightning Nov. 26 at 3:40 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:46 PM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:39 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $1.29 Exit: $2.47 | Profit: 91.92% ROI | https://1ightning.com

0 · Reply

Estimize Nov. 24 at 1:03 PM

Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

KirRoyalTrader Nov. 23 at 10:02 PM

$UVE $INVA $COLL $APPN

0 · Reply

evanmedeiros Nov. 23 at 5:10 PM

0 · Reply

Iightning Nov. 21 at 11:55 PM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $0.93 Exit: $1.68 | Profit: 82.06% ROI | https://1ightning.com

0 · Reply

ZacksResearch Nov. 21 at 1:14 PM

2025 could be the momentum shift $COLL investors have been waiting for. Bold buybacks, a refreshed board, and an expanding ADHD push are all lining up to make this a truly dynamic, transformative year. Full breakdown here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-teaser-21968&ADID=SYND_STOCKTWITS_TWEET_2_2794020_TEASER_21968

0 · Reply

ZacksResearch Nov. 21 at 12:14 PM

$COLL outshines with a 53.4% YTD gain! 🚀 ✨ Q3 2025 adjusted EPS of $2.25 beats the Zacks Consensus Estimate of $1.88. 📊 Revenue for Q3 2025 hits $209.36M, topping consensus & improving from $159.3M a year ago. 💪 Zacks Rank #1 (Strong Buy) highlights their strategic growth initiatives. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-body-21967&ADID=SYND_STOCKTWITS_TWEET_2_2794020_BODY_21967

0 · Reply

Iightning Nov. 21 at 3:15 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $0.93 Exit: $1.68 | Profit: 82.06% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 12:39 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $0.93 Exit: $1.68 | Profit: 82.06% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:52 AM

1ightning® Options Trade Alert (Actionable) | Buy $COLL Dec 19 $50 Call | Enter: $0.93 Exit: $1.68 | Profit: 82.06% ROI | https://1ightning.com

0 · Reply

JR603 Nov. 12 at 10:14 PM

$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!

1 · Reply

Itinerant Nov. 7 at 9:55 PM

$COLL I understand that some investors fear the risk of the opiod litigation and its potential damage to the valuation of COLL. I have added $500 million of such cost into the balance sheet of COLL, and I want to tell you that such a liability is not of serious consequence to the overall valuation of COLL. The company is substantially under valued and can absorb such a settlement cost without difficulty. Of course, I do not really know what such a settlement might prove to be. I am just guessing a number. But you get the idea. Having said that, the market will likely over react to any such settlement, as the market almost always over reacts. JMO

0 · Reply

MarkNewtonCMT Nov. 7 at 9:45 PM

$COLL Collegium Pharma (Gen.Drugs) popped this week out of a tight Cup and Handle formed back in early 2024 and one to certainly keep an eye on going forward. This @marketsurge chart by @IBDinvestors is on William O Neill's screen (85 stocks) & given Healthcare's success lately, still looks technically attractive on this high volume breakout. @InvestorsBusinessDaily

0 · Reply

jewell69 Nov. 7 at 6:58 PM

$COLL sold yesterday 11/6 on great earns day 11/06/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 51 $40.05 $0.01 $2,042.54 up even more today, friday 11/7/25 1:54 pm est 42.31 +another 4.06% for the day

0 · Reply

JarvisFlow Nov. 7 at 3:51 PM

Truist Securities has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 45 → 48.

0 · Reply

JarvisFlow Nov. 7 at 11:41 AM

HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Action List Buy, target set at 44 → 46.

0 · Reply

Market Cap	1.50B
Revenue (ttm)	631.45M
Net Income (ttm)	69.19M
EPS (ttm)	N/A
PE Ratio	7.33
Forward PE	6.91
Profit Margin	10.96%
Debt to Equity Ratio	2.07

Volume	270,000
Avg Vol	459,214
Day's Range	N/A - N/A
Shares Out	31.61M
Stochastic %K	96%
Beta	0.61
Analysts	Strong Sell
Price Target	$46.80